Fig 7C demonstrates that the panel provided additional mutation information not detected by the cobas technology for the three “most actionable” genes: 34.2% (13/38) of BRAF mutations in melanoma, 19.0% (4/19) of EGFR mutations in NSCLC, and 11.1% (4/36) of KRAS mutations in CRC (only samples tested using both the panel and the cobas assay were included in this comparison). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.